Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-label, Registration Directed Phase 2 Study

Drug Category: Array
Conference Category: Array
Lead Author: Fowler N, et al.
Published Date: 04/06/2019
Download Link: /ASCO%202019%20MZL%20Deck%20FINAL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top